Decentralized Clinical Trials (DCT) have gained significant attention in recent years as it brings a new paradigm enriching the clinical trial landscape with a suite of options that transcend the traditional fully on-site demanding participants to be on site for every aspect of the trial.Advances in digital technology coupled with the COVID-19 pandemic acted as a catalyst, encouraging the widespread adoption of hybrid modes of conducting clinical trials to ensure the continuity of clinical research.1 In the aftermath of the pandemic, remote approaches are now an integral part of the clinical trial landscape. This whitepaper explores the benefits and trends of DCTs, spotlighting the Asia Pacific (APAC) Region. Its diverse patient pool, robust healthcare infrastructure, favorable regulations, cost-effectiveness, and technological advancements contribute to the region’s prominence in clinical research.